ATLANTA, March  06, 2026  (GLOBE NEWSWIRE) -- Holzer &amp; Holzer, LLC is investigating whether Nutex Health, Inc. (&#34;Nutex Health&#34; or the &#34;Company&#34;) (NASDAQ:NUTX) complied with federal securities laws. On March 5, 2026,

NUTX

INVESTOR ALERT: Investigation of Nutex Health, Inc. (NUTX) announced by Holzer & Holzer, LLC

Nutex Health Faces Legal Scrutiny After Significant Revenue Drop

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>ATLANTA, March  06, 2026  (GLOBE NEWSWIRE) -- Holzer &amp;amp; Holzer, LLC is investigating whether Nutex Health, Inc. (&amp;#34;Nutex Health&amp;#34; or the &amp;#34;Company&amp;#34;) (NASDAQ:NUTX) complied with federal securities laws. On March 5, 2026,</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Nutex Health’s recent earnings report revealed a steep revenue decline, mainly due to a substantial arbitration adjustment. The subsequent drop in stock price and investigation by Holzer &amp; Holzer could indicate further legal issues and pressure on earnings moving forward.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Nutex Health reported Q4 2025 revenue drop of $105.9 million.</li><li>A $55 million arbitration claim adjustment impacted revenue significantly.</li><li>Nutex&#039;s stock price fell following the disappointing financial results.</li><li>Holzer &amp; Holzer is investigating potential securities law violations.</li><li>Investors are encouraged to seek legal counsel for potential losses.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Holzer &amp; Holzer, LLC</strong>: Investigating Nutex&#039;s compliance with securities laws could lead to further legal action.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under corporate developments as it entails Nutex Health&#039;s financial reporting issues and potential legal ramifications that could significantly affect company operations and stock performance.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Investigation by Holzer &amp; Holzer may lead to further legal repercussions.</li><li>Continued revenue decline could erode investor confidence in NUTX.</li><li>Any legal findings may significantly impact NUTX&#039;s valuation and future prospects.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Nutex Health reported revenue of $151.7 million for Q4 2025.</li><li>Revenue decrease was $105.9 million compared to previous periods.</li><li>$55 million cumulative true-up was due to ineligible arbitration claims.</li><li>Holzer &amp; Holzer initiated an investigation on March 6, 2026.</li><li>Stock price fell immediately after the earnings announcement.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>NUTX may experience downward pressure in stock price due to legal scrutiny and financial performance challenges in the near term.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">ATLANTA, March  06, 2026  (GLOBE NEWSWIRE) -- Holzer &amp; Holzer, LLC is investigating whether Nutex Health, Inc. ("Nutex Health" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/NUTX">NUTX</a>) complied with federal securities laws. On March 5, 2026, Nutex Health announced its financial and operating results for the fourth quarter and fiscal year 2025, revealing a revenue decrease of $105.9 to $151.7 million for the three months ended December 31, 2025 due in part to a "one-time $55.0 million cumulative true-up of 18,950 arbitration claims that arbitrators determined were ineligible under the IDR process. " The price of the Company's stock dropped following this news.</p>  <p align="justify">If you purchased Nutex Health stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at <a href="https://www.globenewswire.com/Tracker?data=RlWMTPc_693URLm37JXhIL2X36iyumBrPQKChM0BX3_QJy4MSJ2ZZAyZE_Kbj4_ZIihxj3N8gLxLZBAmXMokku8bN8Zwbmgj6uQJKdSy2rw=" rel="nofollow" target="_blank">cholzer@holzerlaw.com</a> or Joshua Karr, Esq. at <a href="https://www.globenewswire.com/Tracker?data=fFaOb4zm4rkDTpCbi3xQ1lq4hh6sg-l4sBItNYBBD8g-bhNoQHuasuXxUgW_NUU-dzUn6P6yJ09vUMqbXATSpeokhZ-OZCQYPDWgnFyL-C8=" rel="nofollow" target="_blank">jkarr@holzerlaw.com</a>, call our toll-free number at (888) 508-6832, or visit our website at <a href="https://www.globenewswire.com/Tracker?data=l8OESeeSwm5BqZoxedHuNbivyOsc2WOtYihm_OuR2ylTYDkDPN3gcGMYwO6ee4kM7QU0vmRjnMk8WUWY6aclvoLI12Wl24gkY8TWEwcnqseB-5Dn3tv64t4_CrMm9dp4Pef6_KUlKWVFN5RWWfaQjg==" rel="nofollow" target="_blank">www.holzerlaw.com/case/nutex-health/</a> to discuss your legal rights.</p>  <p align="justify">Holzer &amp; Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, 2023, and 2025 dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer &amp; Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, <a href="https://www.globenewswire.com/Tracker?data=l8OESeeSwm5BqZoxedHuNZ28fP2h38y5yur4-MCFLYJIc74FP0u-QJydbOge4-GEc5rrC5Znyz_z4UYruvu-hTk5S9gi1xlbwazm3-_FFdY=" rel="nofollow" target="_blank">www.holzerlaw.com</a>, and upon request from the firm. Holzer &amp; Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content. </p>  <p align="justify">CONTACT:<br></br>Corey Holzer, Esq.<br></br>(888) 508-6832 (toll-free)<br></br><a href="https://www.globenewswire.com/Tracker?data=RlWMTPc_693URLm37JXhIL2X36iyumBrPQKChM0BX3_QRd33HXzS9PsRwGM45Hm9KZbd7G-XZb-fVN0ARy46yYfBpGRTW1weNe64yPWrALQ=" rel="nofollow" target="_blank">cholzer@holzerlaw.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY2NzYxMSM3NDcyNjcxIzIxODA3Njc="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YjYyZjNmNDUtMWYyNS00ZGE1LTg4MjctMzY3YmQ3MTViNDQ4LTExOTIzMzYtMjAyNi0wMy0wNi1lbg==/tiny/Holzer-Holzer.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/a05f3ad7-8cdf-4723-8365-0c2d9d37b2d3"><img src="https://ml.globenewswire.com/media/a05f3ad7-8cdf-4723-8365-0c2d9d37b2d3/small/hh-logo-2023-300dpi-for-globe-newswire-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

Nutex Health’s recent earnings report revealed a steep revenue decline, mainly due to a substantial arbitration adjustment. The subsequent drop in stock price and investigation by Holzer & Holzer could indicate further legal issues and pressure on earnings moving forward.

INVESTOR ALERT: Investigation of Nutex Health, Inc. (NUTX) announced by Holzer & Holzer, LLC

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News